Deals
Teva Said to Consider Sale of Cancer Portfolio to Reduce Debt
- Israeli drugmaker is speaking to financial advisers on deal
- Oncology treatments reported $1.14 billion in 2016 revenue
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd., the Israeli drugmaker seeking to cut debt after an acquisition spree, is exploring a sale of its specialty cancer treatments, according to people familiar with the matter.
Teva is speaking with financial advisers about the possible sale of the oncology business, which includes treatments for leukemia and a slow-growing form of lymphoma, the people said, asking not to be identified because the deliberations are private. The business could attract private equity bidders and other companies, they said.